Evidence map›Paper›PMID 41040861›Full record

ArticleFrontiers in endocrinology2025

Enhancing post-operative hypothyroidism treatment: rat thyroid autotransplantation into a pre-vascularized, retrievable cell pouch™ device.

Arash Memarnejadian, Pardis Pakshir, Madison Tomlinson, Farideh Berjisian, Ligia Dortas Maffei, Ben Muirhead, Jonathan Mofford, Babak Ataei Mehr, Vijay Parikh, Frank R Shannon and 2 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Arash MemarnejadianR&D Department, Sernova Biotherapeutics Inc., London, ON, Canada.
Pardis PakshirR&D Department, Sernova Biotherapeutics Inc., London, ON, Canada.
Madison TomlinsonR&D Department, Sernova Biotherapeutics Inc., London, ON, Canada.
Farideh BerjisianR&D Department, Sernova Biotherapeutics Inc., London, ON, Canada.
Ligia Dortas MaffeiR&D Department, Sernova Biotherapeutics Inc., London, ON, Canada.
Ben MuirheadDepartment of Chemical Engineering, McMaster University, Hamilton, ON, Canada.
Jonathan MoffordDepartment of Chemical Engineering, McMaster University, Hamilton, ON, Canada.
Babak Ataei MehrR&D Department, Sernova Biotherapeutics Inc., London, ON, Canada.
Vijay ParikhR&D Department, Sernova Biotherapeutics Inc., London, ON, Canada.
Frank R ShannonR&D Department, Sernova Biotherapeutics Inc., London, ON, Canada.
Pericles CaliasR&D Department, Sernova Biotherapeutics Inc., London, ON, Canada.
Philip M ToleikisR&D Department, Sernova Biotherapeutics Inc., London, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: To overcome the limitations of lifelong hormone replacement therapy for post-operative hypothyroidism, we propose autologous thyroid transplantation into the Cell Pouch™ (CP), an implantable and retrievable medical device that supports vascularization and a homeostatic environment for cell grafting. The CP is currently in clinical trials for islet transplantation in type-1 diabetes, demonstrating its capacity to support long-term graft viability. Here, we apply the CP for thyroid tissue transplantation, leveraging the natural gland's regulatory capabilities to benefit patients unresponsive to hormone therapy. Building on previous research validating CP's support for human thyroid grafts in a mouse model, this study evaluates its therapeutic potential in a rat model mimicking clinical thyroidectomy and autologous transplantation. Methods: We used 24 Lewis rats to assess the CP's safety and efficacy. After a five-week post-implantation vascularization period, thyroidectomy was performed in 15 rats, and their glands were transplanted into the CP. A non-transplant group (n=4) underwent thyroidectomy only, and a control group (n=5) received no interventions. Hormone levels (total T3, free T4, TSH) were monitored weekly for 22 weeks. Histology and scintigraphy at endpoint evaluated graft function. Results and Conclusion: Rats with thyroid grafts in the CP restored fT4 and T3 to baseline by weeks 4 and 7, respectively. Explantation reversed this effect. Histological analysis showed well-differentiated follicles with minimal inflammation. Scintigraphy confirmed graft viability. No adverse effects were observed in hematological, liver, or kidney parameters. These findings demonstrate that CP-enabled thyroid transplantation restores function post-thyroidectomy and is safely retrievable, with no residual thyroid tissue, marking a significant safety advancement.

Indexed as

HypothyroidismPostoperative ComplicationsThyroidectomyThyroid GlandAnimalsDisease Models, AnimalHormone Replacement TherapyMaleRatsRats, Inbred LewTransplantation, Autologouspost-surgery hypothyroidismtetraiodothyroninethyroidthyroid stimulating hormonetransplantationtriiodothyronine

Identifiers

PMID41040861
PMCPMC12483921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.